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Abstract  15 
Gastritis is a widely spread inflammatory disease, mostly caused by Helicobacter pylori infection. 16 
Release of IL-8 by the stomach epithelium is a hallmark of gastritis and contributes to the 17 
amplification of the inflammatory state. Pharmacological modulation of IL-8 release is a strategy to 18 
relieve gastric inflammation and prevent more severe clinical outcomes. In search of nutraceuticals 19 
with potential anti-gastritis properties we used a bio-guided approach based on IL-8 secretion by 20 
gastric cells to characterize extracts from the fruits of different chestnut varieties. 21 
 We found that the ability to inhibit IL-8 secretion correlated with the amount of proanthocyanidins 22 
and was associated to the not edible parts of chestnut in all the tested varieties. We also found that 23 
the anti-inflammatory activity is preserved upon mild thermal treatment and after in vitro simulated 24 
gastric digestion. 25 
By combining a robust bio-guided approach with a comprehensive analysis of the tannin fraction of 26 
chestnut extracts, we provide evidence for the potential use of chestnut-based nutraceuticals in 27 
human gastritis. The bioactive components of chestnut fruits inhibit IL-8 secretion by impairing NF-28 
κB signaling and by other mechanisms, thus opening new applications of proanthocyanidins for 29 
inflammation-based diseases. 30 
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 37 
1. Introduction 38 
Gastritis is a very common inflammatory disease, mostly caused by Helicobacter pylori (H. pylori) 39 
infection [1]. This gram negative bacterium colonizes the gastric mucosa of over 80% of people in 40 
developing countries [2] and at least 50% of the world human population [3]. H. pylori infection 41 
induces a strong immune response in the host [4], which is characterized by the release of several 42 
 inflammatory cytokines in the gastric mucosa, including IL-8 and TNFα [5-8]. Gastric epithelial cells 43 
exposed to cytokines, mostly TNFα and IL-1β, release IL-8, a potent chemokine, which promotes 44 
neutrophil infiltration [9-11]. IL-8 secretion is a typical hallmark in H. pylori-induced gastritis [12], 45 
and its release by gastric epithelial cells is strictly associated with the activation of NF-κB [9, 13], a 46 
transcription factor involved in a multitude of patho-physiological processes, including 47 
inflammation, cell growth, and proliferation [14-16]. 48 
Plants rich in tannins have a traditional use for treating gastric ulcer; moreover, tannins showed anti-49 
bacterial activity against H. pylori [17, 18], and inhibition of gastric IL-8 release, both in vitro and in 50 
vivo [19, 20]. Epidemiological studies indicate that dietary consumption of proanthocyanidins 51 
(condensed tannins) has beneficial effects on a variety of chronic diseases, including metabolic 52 
syndrome, atherosclerosis, and cancer [21, 22]. Moreover, proanthocyanidins have been found 53 
unchanged after in vitro simulated gastric digestion [19], and in vivo at gastric level [23, 24], thus 54 
suggesting that the biological activity may occur in situ. 55 
Chestnut tree (Castanea sativa Mill., sin. Castanea vesca Gaertn.) is a rich source of tannins, mostly in 56 
leaves, wood and bark, whereas fruits, which are a good source of essential dietary nutrients, showed 57 
lower levels of polyphenols [25]. In Italy, chestnuts from six geographical areas are regulated by 58 
Protected Geographic Indication (PGI) under European Union law and the average production of 59 
this fruit in the period 2003-2013 was close to 49,000 tons/year [26]. Despite high production of 60 
chestnut and the traditional dietary consumption in several European countries, only limited data on 61 
the tannin composition of fruits and their beneficial properties occur in the literature. Few studies 62 
performed on chestnut industrial by-products reported high content of phenols and marked 63 
 antioxidant properties [27, 28]. Tannins were identified in fruits, although more precise details on 64 
their chemical features were not reported [29-31]. 65 
The aim of this study was to characterize the anti-inflammatory properties of chestnut bioactive 66 
compounds, taking into consideration several variables (chestnut fruit parts, chestnut varieties, 67 
harvest year, chemical and thermal stability, etc). To this end we used a bio-guided approach based 68 
on IL-8 secretion by AGS cells stimulated with TNFa, a simple but validated model of gastritis 69 
induced by H. pylori. 70 
2. Materials and Methods  71 
2.1. Materials 72 
Dulbecco’s Modified Eagle’s Medium/F12 (DMEM)/F12 (1:1), penicillin, streptomycin, L-73 
glutamine and trypsin-EDTA were from Gibco (Life Technologies Italia, Monza, Italy). Foetal bovine 74 
serum (FBS), and disposable materials for cell culture were purchased by Euroclone (Euro- clone 75 
S.p.A., Pero-Milan, Italy). Human adenocarcinoma cells (AGS, CRL-1739) were purchased from LGC 76 
Standard S.r.l., Milano, Italy.  77 
The reagent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and curcumin 78 
were from Sigma Aldrich (Milan, Italy). All reagents used for the biological assays were HPLC grade. 79 
Human TNFα and Human IL-8 Elisa Development Kit were from Peprotech Inc. (London, UK). All 80 
chromatographic solvents were HPLC grade or LC-MS grade for MS experiments. Acetonitrile, 81 
methanol, ethanol, formic acid, hydrochloric acid, vanillin, and iron sulfate were from Sigma Aldrich 82 
(Milan, Italy). 83 
2.2. Plant material and preparation of the extracts 84 
Chestnuts from five varieties (Venégon, Paié, Russirö, Verdésa and Piliscé) of Castanea sativa 85 
Mill. were collected by the farmer consortium in the regional area of Campo dei Fiori (Varese, Italy).  86 
 Fresh fruits were maintained under vacuum at 4 °C until extraction. To obtain the extracts 2,5 87 
grams of milled whole fruit were extracted twice with 50 mL of water (aqueous extract) or 88 
ethanol/water 50:50 (hydroalcoholic extract) for 4 and 16 hours, respectively, at room temperature 89 
under dark conditions. The mixture was filtered through Supervelox filter paper in order to remove 90 
plant debris; the extracts obtained were frozen with dry ice and alcohol and placed at −80 °C 91 
overnight, then lyophilized and maintained at −20 °C. In general, the yields of the aqueous and 92 
hydroalcoholic extracts of the same variety were comparable with the exception of Verdésa, whose 93 
hydroalcoholic yield was the half of the aqueous one. 94 
Three parts of the fruits, endosperm (kernel) and the outer parts episperm (which directly covers 95 
the kernel) and pericarp (the woody part), were separated and extracted with hydroalcoholic solvent 96 
following the procedure previously described. The yield of the different parts varied according to the 97 
variety. 98 
The yields (w/w) of each extraction were calculated as percentage of the dried extract weight in 99 
respect to the weight of the fresh starting material. The yields of the extracts are reported in the 100 
supplementary materials (Table S1).  101 
Commercially available flour, produced from the endosperm of dried chestnut (variety 102 
Venégon), and relative industrial by-product, constituted by episperm and pericarp, were extracted 103 
by hydroalcoholic solvent. Before proceeding with the biological evaluation, the extracts were 104 
dissolved in sterilized distilled water and DMSO (25%) at a concentration of 30 mg/mL, then stored 105 
in aliquots at −20 °C. For the biochemical analysis, the lyophilized samples (10 mg) were dissolved in 106 
5 mL of a mixture of methanol/water (2/1). 107 
2.3. Cytotoxicity 108 
The integrity of the cell morphology before and after treatment was assessed by light microscope 109 
inspection. Cell viability was measured, after 6 h treatment, by the 3,4,5-dimethylthiazol- 2-yl-2-5-110 
diphenyltetrazolium bromide (MTT) method. This method evaluates the activity of a mitochondrial 111 
 enzyme, which is an index of cell viability. The extracts did not show cytotoxicity at each 112 
concentration tested.  113 
2.4. Cell culture and IL-8 release measurement 114 
AGS cells were grown at 37 °C in DMEM F12 supplemented with 100 units penicillin per mL, 115 
100 mg streptomycin per mL, 2 mM L-glutamine, and 10% heat-inactivated FBS (Euroclone S.p.A, 116 
Pero, Italy), under a humidified atmosphere containing 5% CO2.  117 
Cells were grown in 24-well plates for 48 h (30 000 cells per well) before the cytokine treatment. 118 
The IL-8 secretion, induced by TNFα at 10 ng/mL, was tested after 6 h treatment in the presence of 119 
un-digested or digested extracts (0,1–100 µg/mL). Curcumin (10 µM) was used as the reference 120 
inhibitor of IL-8 secretion (80% inhibition). IL-8 was quantified using a Human Interleukin-8 ELISA 121 
Development Kit as described below. Briefly, Corning 96 well EIA/RIA plates from Sigma- Aldrich 122 
(Milan, Italy) were coated with the antibody provided in the ELISA Kit (Peprotech Inc., London, UK) 123 
overnight at 4 °C. After blocking the reaction, 200 µl of samples in duplicate were transferred into 124 
wells at room temperature for 1 h. The amount of IL-8 in the samples was detected by spectroscopy 125 
(signal read: 450 nm, 0.1 s) by the use of biotinylated and streptavidin–HRP conjugate antibodies, 126 
evaluating the 3,3′,5,5′-tetramethylbenzidine (TMB) substrate reaction. Quantification of IL-8 was 127 
done using an optimized standard curve supplied with the ELISA Kit (8.0–1000.0 pg/mL).  128 
2.5. NF-κB driven transcription 129 
To evaluate the NF-κB driven transcription, AGS cells were plated in 24-well plates (30,000 cells 130 
per well). After 48 h, cells were transiently transfected by the calcium-phosphate method with the 131 
reporter plasmid (NF-κB-LUC, 50 ng/well) containing the luciferase gene under control of three κB 132 
responsive elements. The plasmid NF-κB-LUC was a gift of Dr. N. Marx (Department of Internal 133 
medicine-Cardiology, University of Ulm, Ulm, Germany). After 16 h, the cells were treated with the 134 
stimulus (TNFα 10 ng/mL) and the extract for 6 h. Curcumin (10 µM) was used as the reference 135 
inhibitor. At the end of this time, cells were harvested and the luciferase assay was performed using 136 
 the BriteliteTM Plus reagent (PerkinElmer Inc., Walthman, MA, USA) according to the manufacturer’s 137 
instructions. Data were expressed considering 100% of the luciferase activity related to the cytokine-138 
induced promoter activity. 139 
2.6. Total Phenol Content Assay 140 
Total polyphenol content was determined according to Folin–Ciocalteu’s method, as reported 141 
by Singleton and Rossi [32]. Freeze-dried samples (50 mg) were solubilized in 1 mL of a 50:50 142 
water:methanol solution. Aliquots of 300 µL from different samples were mixed in test tubes with 1.5 143 
mL of Folin–Ciocalteu’s reagent diluted 10 times, and 1.2 mL of 7.5% (w/v) sodium carbonate. After 144 
30 min, the absorbance was measured at 765 nm in a UV-visible spectrophotometer (Varian Cary 50 145 
SCAN, Palo Alto, CA, USA). The polyphenol content in samples was calculated using a standard 146 
curve of Gallic acid. Results were expressed as equivalents of Gallic acid in mg/g.   147 
2.7. In vitro gastric digestion 148 
According to a well-established protocol, the gastric digestion was simulated using an in vitro 149 
approach previously described [33]. Briefly, the extracts (100 mg) were incubated for 5 minutes at 37 150 
°C with 6 mL saliva juice, then 12 mL gastric juice were added to the suspension and the sample was 151 
incubated for 2 hours at 37 °C. At the end of the incubation, the digested sample was centrifuged for 152 
5 minutes at 3000g and the supernatant frozen and lyophilized. All the samples were then stored at 153 
−20 °C until use for biological assays. 154 
2.8. Evaluation of Thermal Stability 155 
Heating treatment was performed directly on 10 mg of dried extracts, placed in pyrex vials, 156 
using a stove (Tecnovetro s.r.l., Monza, Italy) at different temperatures. The extracts were placed in 157 
the stove once the selected temperature was reached. The temperature was additionally controlled 158 
by a second thermometer during the incubation time. The heating treatment at 50°C reflected the 159 
temperature reached by the fruit during the industrial drying process, while 100°C was selected as 160 
 boiling temperature, the same used for boiled chestnut preparation. After heating, 1-2 milligrams of 161 
the extract were weighted and solved in a mix of water and DMSO (3:1). The highest heating time 162 
(6h) at 100°C led to carbonized insoluble particles, thus the extracts were centrifuged after the 163 
addition of the solvent to remove insoluble residues. 164 
2.9. UPLC-MS/MS method for multiple classes of phenolics 165 
Phenolic compounds were determined according to a previous method [34]. Briefly, an aliquot 166 
of the extract was filtered 0.22 µm in a HPLC vial. Chromatographic analysis was performed using a 167 
Waters Acquity UPLC system (Milford, USA) with a Waters Acquity HSS T3 column (100 mmx2.1 168 
mm; 1.8 µm). The flow was 0.4 mL/min and the gradient profile was 5% B for the initial condition; 169 
from 0 to 3 min linear gradient to 20% B; from 3 to 4.3 min, isocratic 20% B; from 4.3 to 9 linear gradient 170 
to 45% B; from 9 to 11 min, linear gradient to 100% B; from 11 to 13 min wash at 100% B and then 171 
from 13.01 to 15 min back to the initial conditions (B: acetonitrile containing 0.1% formic acid; A: 172 
water containing 0.1% formic acid). Mass spectrometry detection was performed on a Waters Xevo 173 
triple-quadrupole mass spectrometer detector (Milford, USA) with an electrospray (ESI) source [34]. 174 
A total of 24 polyphenols were identified among the samples and proper calibration curves were 175 
obtained for each individual compound for precise quantification. 176 
2.10. Analysis of proanthocyanidins 177 
The assay to determine the quantity of proanthocyanidins was based on their transformation 178 
into anthocyanidins, in a warm, acid environment [35]. 0.5 mL of the initial extract and 2.5 mL of 179 
MeOH were collected in a 50 mL flask, shielded from light with aluminum foil, containing 9.5 mL 180 
absolute EtOH. 12.5 mL of FeSO4 in concentrated HCl (300 mg/L) were added to the mixture and 181 
then immediately placed in a boiling water bath and refluxed for 50 min. After 10 min at room 182 
temperature, the spectrum from 380 to 700 nm was recorded in a 10 mm cell, against a blank (water). 183 
The tangent from the minimum (450 nm) was drawn, and the absorbance between the maximum (550 184 
nm) and the tangent was measured. To subtract natural anthocyanins present in the sample, which 185 
 can interfere with the assay, 0.5 mL of the extract was prepared under the same conditions, however, 186 
in this case the reaction was carried out in an ice bath and the absorbance obtained was then 187 
subtracted to obtain the net absorbance value. The proanthocyanidins concentration (mg/g) can 188 
conventionally be expressed as the cyanidin formed. Further information is available in the literature 189 
[35-37]. 190 
2.11. Analysis of index of vanillin 191 
The catechins and proanthocyanidins reactive to vanillin were analyzed according to the 192 
optimized and controlled vanillin-HCl method of Broadhurst and Jones [37, 38], following the 193 
conditions described by Di Stefano et al. [39]. 0.5 mL of the initial extract and 0.5 mL of MeOH were 194 
collected in a 50 mL flask, shielded from light with aluminum foil, 6 mL of vanillin (4% in methanol) 195 
were added in the flask and 3 mL of HCl. To subtract the natural interference, 0.5 mL of the extract 196 
was prepared under the same conditions, was used 6 mL of pure methanol instead of vanillin 197 
solution. The absorbance was measured at 500 nm in a 10 mm cell, against a blank reaction. 198 
Concentrations were calculated as (+)-catechin (mg/g). 199 
2.12. HPLC analysis of Procyanidins 200 
The PA subunit composition, percentage of galloylation (%G), percentage of prodelphinidins 201 
(%P), and mean degree of polymerisation (mDP), were determined after acid-catalysis in the presence 202 
of excess phloroglucinol (phloroglucinolysis) [40]. One hundred microliters of the sample were added 203 
to 900 µL of methanol and water (50/50 v/ v), filtered, and injected into the LC-MS system. One 204 
hundred microliters of sample were added to 100 µL of phloroglucinol reagent at 50 °C for 30 min 205 
and then combined with 1 mL of sodium acetate to stop the reaction. The samples were filtered and 206 
immediately analysed. 207 
2.13. Statistical Analysis 208 
 All data are expressed as mean ± s.d.; data were analyzed by unpaired one-way analysis of 209 
variance (ANOVA) followed by Bonferroni as post-hoc test. Statistical analyses were done using 210 
GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, CA, USA). p < 0.05 was considered 211 
statistically significant. IC50 was calculated using GraphPad Prism 5.00 software.   212 
3. Results 213 
3.1. Anti-inflammatory effects of chestnut extracts in Human Gastric Epithelial (AGS) Cells 214 
The first step in the bio-guided approach used in the present study was the preparation of 215 
aqueous and hydroalcoholic extracts from freshly collected whole chestnut fruits from five varieties 216 
of Castanea sativa Mill. The yields of the extracts are reported in the supplementary materials (Table 217 
S1). None of the tested extracts displayed cytotoxic effects on AGS cells, evaluated by the MTT test 218 
(data not shown). We then assayed the potential anti-gastritis properties of chestnut fruit extracts (10 219 
µg/ml) by measuring the amount of IL-8 released by AGS cells treated with TNFa for 6 h. As shown 220 
in figure 1, only the extracts from Paié, Venégon, and Verdésa significantly prevented IL-8 release, 221 
and in all three cases the hydroalcoholic extracts exhibited higher inhibitory effect (fig. 1, panel B vs 222 





Total phenols  





Total phenols  
(GAE) mg/g ± s.d. 
 Paié 32.38 ± 2.71  Paié 37.10 ± 7.66 
 Piliscé 18.40 ± 0.61  Piliscé 17.43 ± 3.15 
 Russirö 13.50 ± 0.92  Russirö 7.80 ± 3.46 
  Venégon 45.00 ± 6.61  Venégon 42.80 ± 8.25 
 Verdésa 44.07 ± 2.38  Verdésa 96.67 ± 8.13 
Paié (Pai); Piliscé (Pil); Russirö (Rus); Venégon (Ven.); Verdésa (Ver.). Total phenols results are expressed as mg gallic 225 
acid equivalents (GAE)/g extract and are the mean ± standard deviations (s.d.) 226 
Figure 1. Effect of aqueous (A) and hydroalcoholic (B) extracts (10 µg/mL) from chestnuts of 5 different 227 
varieties on IL-8 secretion in TNFα-treated AGS cells. Amount of total phenols measured in each 228 
extract (C). 229 
The total phenol content in the extracts ranged between 7.80 and 96.67 mg, expressed as gallic 230 
acid equivalents (GAE)/g of extract. The highest content was found in Verdésa and Venégon extracts, 231 
both aqueous and hydroalcoholic, as shown in Figure 1, panel C. In general, the anti-inflammatory 232 
activity paralleled the total phenol content. Notably, in the case of Verdésa the use of the 233 
hydroalcoholic mixture was more efficient in extracting the phenolic fraction (96.67 vs 44.07 mg/g), 234 
thus suggesting a variety-specific composition of phenolic compounds exhibiting different physico-235 
chemical properties. 236 
The extracts from the most active varieties were further investigated in concentration-response 237 
experiments ranging from 0.5 to 100 µg/mL for the aqueous extracts (Figure 2A) and from 0.1 to 10 238 
µg/mL for the hydroalcoholic extracts (Figure 2B).  239 
 240 









Paié 21.01 ± 7.09 1.85 ± 1.34 
Venégon 10.22 ± 2.54 1.5 ± 0.52 
Verdésa 1.44 ± 0.32 0.75 ± 0.09 
 Figure 2. Release of IL-8 by AGS cells treated with TNFa in the presence of aqueous (A) and 244 
hydroalcoholic (B) extracts from chestnut varieties. 245 
All the aqueous and hydroalcoholic extracts inhibited the release of IL-8 in a concentration-246 
dependent manner and, as expected, the hydroalcoholic extracts showed IC50s between 2 and 11 times 247 
lower compared to the corresponding aqueous counterparts (fig. 2C). Based on these results, the 248 
hydroalcoholic extracts were selected for further investigations. 249 
Since TNFa-induced expression of IL-8 depends on the NF-κB activation, we assayed the ability 250 
of hydroalcoholic extracts to modulate NF-κB driven transcription. AGS cells were transiently 251 
transfected with the NF-κB-luc reporter plasmid and treated for 6 h with the extracts at 10 µg/mL in 252 
the presence of TNFα (10 ng/mL). The inhibitory effects of the extracts were statistically significant 253 
only for the varieties Venégon and Verdésa. Furthermore, while the TNFa-induced release of IL-8 254 
was completely prevented by 10 µg/mL Venégon and Verdésa hydroalcoholic extracts (fig. 1B), at the 255 
same concentration the NF-κB-driven transcription was inhibited only by 50-60%. Nevertheless, these 256 
results confirm that the NF-κB pathway is a key molecular target of chestnut bioactive compounds. 257 
 258 
Figure 3. Effect hydroalcoholic extracts (10 µg/mL) from chestnuts of 5 different varieties on NF-kB 259 
driven transcription in TNFα-treated AGS cells. 260 
Since in some cases, plant extracts, as single treatment, may induce an inflammatory 261 
response we evaluated the release of IL-8 and NF-κB-driven transcription in AGS cells treated 262 
with 10 µg/ml hydroalcoholic extract from the five chestnut varieties in the absence of TNFα. We 263 
 found no change of IL-8 secretion nor of promoter activity upon 6 h treatment with the five 264 
extracts, thus excluding inflammatory effects in untreated cells (data not shown).  265 
To get insights into the chemical entities contributing to the biological activity, we performed 266 
a detailed phytochemical characterization of the hydroalcoholic extracts from the five chestnut 267 
varieties, by UPLC-MS/MS. As reported in Table 1, we identified different classes of compounds, 268 
including condensed tannins (e.g. proanthocyanidins), flavonoids (e.g. catechins), stilbenes (e.g. 269 
resveratrol), and phenolic acids (e.g. gallic and ellagic acids). The most active varieties (Paié, 270 
Venégon, Verdésa) contained significant levels (> 20 mg/g of extract) of high molecular weight 271 
proanthocyanidins, with a mean degree of polymerization (mDP) ranging between 3.2 (Venégon) 272 
to 6.7 (Piliscé). In contrast, these compounds were undetectable, in the least active variety, 273 
Russirò, thus suggesting that this class of molecules is a major contributor to the anti-274 
inflammatory activity shown above. Considering the extraction efficiency, proanthocyanidins 275 
ranged from 0 to 1.75 mg/g of the whole fruit (Table 1, last bottom line). 276 
  LOQ 
mg 
 Paié  Piliscé  Russirö  Venégon  Verdésa 
            
               Gallic acid mg/g 0,01  1.40  0.21  0.17  1.34  0.59 
Ellagic acid mg/g 0,10  3.71  0.60  0.41  5.43  1.32 
Vanillin reaction (+) 
catechin mg/g 0,1  6.3  4.9  3.8  12.6  62.5 
Proanthocyanidin B.S. 
(HMWP) mg/g 2,0  10.1  4.8  n.d.  26.7  147.1 
Flavanol monomers µg/g   0.1  0.0  0.0  0.1  0.5 
Procyanidins dimers µg/g   0.0  0.0  0.0  0.0  0.1 
Procyanidins oligomers µg/g   2.4  0.7  0.5  3.3  13.3 
mDP %   3.8  6.7  4.6  3.2  5.2 
p-hydroxybenzoic acid µg/g 0,50  24.44  6.04  3.19  38.63  5.53 
Vanillic acid µg/g 0,10  32.82  5.13  2.97  30.73  1.01 
Caffeic acid µg/g 0,02  3.79  0.03  n.d.  5.79  n.d. 
Ferulic acid µg/g 0,01  64.32  2.76  2.24  95.65  1.43 
Sinapic acid µg/g 2,00  213.43  n.d.  3.37  81.87  28.03 
t-coutaric acid µg/g 0,05  8.09  12.36  15.66  6.43  1.01 
t-resveratrol µg/g 2,00  12.98  3.18  2.42  14.49  9.91 
t-piceide µg/g 1,00  9.09  1.59  1.44  7.29  8.80 
Phlorizin µg/g 0,10  n.d.  0.57  1.38  n.d.  25.45 
Luteolin µg/g 0,20  1.28  n.d.  n.d.  0.58  n.d. 
Naringenin µg/g 0,20  16.57  0.99  n.d.  17.20  1.63 
Catechin µg/g 5,00  92.50  12.38  6.02  306.05  272.39 
  277 
Table 1. 278 
Phytochemical 279 
characterization of the hydroalcoholic extracts from the five chestnut varieties  280 
In summary, we found that chestnuts contain bioactive compounds that inhibit the TNFa-281 
induced secretion of IL-8 by gastric cells, by interfering, at least in part, with the NF-κB pathway. 282 
The content in bioactive compounds with anti-inflammatory properties varied among the five 283 
varieties and the hydroalcoholic mixture resulted the most efficient solvent to extract active 284 
molecules. The ability to inhibit IL-8 secretion correlated with the amount of proanthocyanidins 285 
in the tested extracts. 286 
3.2. Contribution of the fruit parts to the biological activity 287 
 To investigate the contribution of the various parts of the fruit to the biological activity, 288 
hydroalcoholic extracts from the edible (endosperm) and not edible (pericarp and episperm) parts 289 
were prepared separately, as described in section 2.2. In the biological assays, we tested the varieties 290 
that resulted more active, i.e. Paié, Venégon and Verdésa (fig. 1 and 2). 291 
The extracts obtained from endosperm, the edible part, were not active on IL-8 release till the 292 
maximum concentration tested (100 µg/mL) (Figure 4A). On the contrary, the hydroalcoholic extracts 293 
from pericarp and episperm showed a concentration dependent inhibitory activity (Figure 4B and 294 
4C, respectively). 295 
Gallocatechin µg/g 100,00  549.40  121.10  n.d.  611.47  493.53 
Procyanidin B1 µg/g 20,00  n.d.  n.d.  n.d.  n.d.  89.43 
Procyanidin B3 (as B1) µg/g 20,00  n.d.  n.d.  n.d.  n.d.  86.51 
Taxifolin µg/g 0,50  n.d.  n.d.  n.d.  n.d.  0.80 
Quercetin-3-Rha µg/g 0,20  n.d.  n.d.  n.d.  0.31  n.d. 
Kaempferol-3-Glc µg/g 0,20  n.d.  n.d.  n.d.  n.d.  n.d. 
Isorhamnetin-3-Glc µg/g 0,10  1.92  0.49  0.30  3.49  1.25 
Isorhamnetin-3- 
rutinoside µg/g 0,20  n.d.  n.d.  n.d.  n.d.  n.d. 
Quercetin-3- 
glucuronide µg/g 0,20  0.64  n.d.  n.d.  0.35  n.d. 
Quercetin-3-Glc + 
quercetin-3-Gal µg/g 0,10 
 0.52  n.d.  n.d.  2.09  0.10 
Proanthocyanidins  
in the whole fruit mg/g 2,0  0.13  0.04  n.d.  0.21  1.75 




Figure 4. Hydroalcoholic extracts from pericarp (B) and episperm (C) inhibit IL-8 secretion in TNFα-300 
treated AGS cells, while extract from endosperm (A) is inactive at the concentrations tested 301 
The two varieties active on NF-κB signaling, Venégon and Verdésa (fig. 3), were further 302 
investigated; the corresponding hydroalcoholic extracts, either from pericarp (Figure 5B) and 303 
episperm (Figure 5C), impaired the NF-κB driven transcription challenged by TNFα in a 304 
concentration dependent manner. The hydroalcoholic extracts from endosperm displayed no activity 305 
at any of the tested concentrations (Figure 5A). 306 
IC50  
µg/mL ± s.d. Pericarp Episperm 
Paié 0.28 ± 0.10 0.42 ± 0.12 
Venégon 0.15 ± 0.08 0.14 ± 0.04 
Verdésa 0.37 ± 0.08 0.22 ± 0.04 




Figure 5. Effect of hydroalcoholic extracts (10 µg/mL) of the fruit parts from Venégon and Verdésa 311 
varietes on NF-kB driven transcription in TNFα-treated AGS cells 312 
IC50  
µg/mL ± s.d. Pericarp Episperm 
Venégon 1.97 ± 0.94 1.5 ± 1.15 














Table 2. Phytochemical characterization of the hydroalcoholic extracts of the fruit parts from the five chestnut varieties 326 
  LOQ 
mg 
 Paié  Piliscé Russirö  Venégon          Verdésa 
   End. Epi. Per. End. Epi. Per.  End. Epi. Per.  End. Epi. Per.  End. Epi. Per. 
                        Gallic acid mg/g 0,01  n.d. 3.42 1.98 0.03 1.38 0.89  0.01 1.04 0.74  n.d. 2.65 1.74  0.09 0.49 0.82 
Ellagic acid mg/g 0,10  1.17 1.66 18.19 0.79 4.24 20.97  0.24 4.27 23.61  0.53 3.73 15.54  0.52 1.03 4.97 Vanillin reaction (+) 
catechin mg/g 0,1  6.4 387.5 90.4 9.3 114.7 45.9  3.5 7.9 15.8  5.5 303.8 50.6  0.1 676.0 281.9 
Proanthocyanidin B.S. 
(HMWP) mg/g 2,0  n.d. 687.3 145.1 n.d. 235.7 76.6  n.d. 4.2 25.6  n.d. 651.4 150.2  n.d. 921.0 378.9 
Flavanol monomers µg/g   0.0 1.7 0.9 0.0 0.6 0.3  0.0 0.1 0.1  0.0 1.6 0.6  0.0 1.3 2.6 
Procyanidins dimers µg/g   0.0 0.4 0.2 0.0 0.0 0.3  0.0 0.0 0.0  0.0 0.5 0.6  0.0 0.2 3.5 
Procyanidins oligomers µg/g   0.7 11.1 211.1 0.7 53.1 7.5  0.1 0.7 2.2  0.7 13.4 188.6  0.1 352.4 112.8 
mDP %   1.0 2.3 11.8 1.3 9.1 3.3  1.0 1.7 1.8  1.3 2.9 8.2  1.5 13.2 5.0 
p-hydroxybenzoic acid µg/g 0,50  14.39 38.13 85.80 11.98 29.52 37.76  13.13 69.38 60.82  33.77 30.61 62.71  0.80 3.97 12.22 
Vanillic acid µg/g 0,10  37.95 25.39 60.54 4.55 21.11 22.19  2.57 7.54 11.35  21.57 16.29 45.27  0.92 0.83 3.98 
Caffeic acid µg/g 0,02  1.08 2.48 6.47 0.05 0.18 0.07  n.d. n.d. n.d.  0.76 9.56 1.83  0.58 0.02 n.d. 
Ferulic acid µg/g 0,01  25.08 11.76 2.59 1.56 2.07 0.27  0.01 0.25 0.35  21.52 47.47 11.14  8.43 1.85 1.58 
Sinapic acid µg/g 2,00  61.86 127.46 n.d. n.d. n.d. n.d.  n.d. n.d. n.d.  56.90 143.20 n.d.  53.43 n.d. n.d. 
t-coutaric acid µg/g 0,05  41.36 37.42 3.65 5.19 n.d. n.d.  5.50 1.41 n.d.  47.51 26.78 37.79  8.05 6.65 41.60 
t-resveratrol µg/g 2,00  n.d. 89.37 46.02 n.d. 16.60 12.84  n.d. n.d. 5.03  n.d. 38.17 30.54  n.d. 36.94 48.50 
t-piceide µg/g 1,00  5.77 25.80 20.82 n.d. 8.02 4.86  n.d. 2.33 3.02  7.38 21.05 16.96  n.d. 3.03 8.87 
Phlorizin µg/g 0,10  n.d. 17.91 34.69 n.d. 1.23 7.78  n.d. 0.12 0.55  n.d. 16.09 53.13  0.52 22.48 13.88 
Luteolin µg/g 0,20  n.d. 1.34 11.00 n.d. 0.28 5.79  n.d. n.d. 2.26  0.28 0.40 7.44  n.d. 0.35 9.31 
Naringenin µg/g 0,20  5.75 74.68 47.06 n.d. 3.29 5.19  n.d. n.d. 0.55  5.14 39.98 54.54  1.09 14.09 20.62 
Catechin µg/g 5,00  n.d. 1533.04 2231.3
6 
n.d. 170.38 213.67  n.d. 11.73 154.43  22.95 1974.71 1648.55  n.d. 286.76 1942.00 
Gallocatechin µg/g 100,00  n.d. 1642.02 613.70 n.d. 547.02 356.55  141.87 216.17 n.d.  n.d. 1228.70 571.09  n.d. 611.34 486.20 
Procyanidin B1 µg/g 20,00  n.d. 249.47 1056.2
2 
n.d. n.d. 104.56  n.d. n.d. 59.62  n.d. 507.95 941.71  n.d. 62.12 827.09 
Procyanidin B3 (as B1) µg/g 20,00  n.d. 287.11 336.46 n.d. n.d. 81.10  n.d. n.d. 52.88  n.d. 1193.32 319.10  n.d. 69.82 378.94 
Taxifolin µg/g 0,50  n.d. 18.44 18.08 n.d. n.d. 2.10  n.d. n.d. 1.02  n.d. 19.67 17.71  n.d. 1.18 13.17 
Quercetin-3-Rha µg/g 0,20  n.d. 0.75 3.02 n.d. n.d. n.d.  n.d. n.d. n.d.  n.d. 0.86 7.48  n.d. n.d. 4.50 
Kaempferol-3-Glc µg/g 0,20  n.d. n.d. 2.97 n.d. n.d. 1.03  n.d. n.d. n.d.  n.d. n.d. 1.40  0.43 n.d. 0.47 
Isorhamnetin-3-Glc µg/g 0,10  n.d. 3.94 102.86 n.d. n.d. 8.48  n.d. n.d. 0.97  n.d. 1.94 135.92  n.d. 0.20 47.24 Isorhamnetin-3- 
rutinoside µg/g 0,20  n.d. 0.97 5.82 n.d. n.d. n.d.  n.d. n.d. n.d.  n.d. 1.37 4.48  n.d. n.d. 0.83 
Quercetin-3- 
glucuronide µg/g 0,20  15.03 0.69 41.21 n.d. n.d. n.d.  n.d. n.d. n.d.  0.63 0.28 5.58  n.d. n.d. 0.63 
Quercetin-3-Glc + 
quercetin-3-Gal µg/g 0,10 
 5.25 1.47 23.77 n.d. 0.14 0.53  n.d. n.d. 0.69  0.43 0.75 10.55  0.29 0.20 4.42 
The finding that none of the extracts from the edible part (endosperm) of the most active 327 
varieties displayed biological activity (fig. 4A and 5A) prompted us to investigate in more detail 328 
the phytochemical composition of the various extracts. As reported in Table 2, high molecular 329 
weight proanthocyanidins, the putative bioactive fraction, were enriched (>650 mg/g) in the 330 
extracts obtained from the episperm of Paiè, Venégon and Verdésa. The same applies to the 331 
extracts prepared from the pericarp, with concentration ranging from 145.1 mg/g (Paié) to 378.9 332 
mg/g (Verdésa). The variety Verdesa resulted the richest source of high molecular weight 333 
proanthocyanidins, which accounted to about 90% of the episperm extract. Russirò, the variety 334 
exhibiting the lowest anti-inflammatory activity (fig. 1B), resulted almost devoid of 335 
proantocyanidins in any part. The anti-inflammatory activity resulted unrelated to the mean 336 
degree of polymerization (mDP) of proanthocyanydins. In fact, for example, the extracts from 337 
both pericarp and episperm of Venégon fruits displayed IC50 of about 0.15 µg/mL (Fig. 4D), while 338 
the mDP accounted to 8.2 and 2.9, respectively. 339 
 The results shown above indicate that the biological activity is associated to the not edible 340 
parts of chestnut (pericarp and endosperm) in all the tested varieties. The phytochemical analysis 341 
confirmed that the hydroalcoholic extracts exhibiting the highest anti-inflammatory activity were 342 
richest in high molecular weight proanthocyanidins; the observation corroborates the hypothesis 343 
that these compounds confer to chestnut extracts the ability to prevent IL-8 secretion. 344 
3.3. Effect of extrinsic variables on the biological activity of chestnut varieties 345 
Chestnuts are widely used in food industry for sweets and flour production, through procedures 346 
that require heating. Therefore, we evaluated the anti-inflammatory property of hydroalcoholic 347 
extracts from Verdésa and Venégon chestnuts upon exposure to mild (50°C) and high (100°C) 348 
temperature, as described in section 2.2. As shown in Figure 6A, when heated at 50°C up to 6 h, both 349 
extracts maintained the inhibitory activity on IL-8 secretion. However, both extracts exhibited 350 
reduced activity upon exposure at 100°C in a time dependent manner; of note, the inhibitory effect 351 
was almost completely lost after 2 h of incubation at 100°C (Figure 6B). 352 
  353 
Figure 6. Heating treatment of dried hydroalcoholic extracts from chestnuts varieties: (A) the extracts 354 
inhibit IL-8 secretion in TNFα-treated AGS cells after heating at 50 °C for 6h. (B) time and temperature 355 
dependent loss of IL-8 inhibition in TNFα-treated AGS cells during heating at 100 °C 356 
The results shown so far refer to extracts prepared from fruits harvested in the year 2015. It is 357 
known that the quali-quantitative composition in bioactive compounds of medicinal and edible 358 
plants varies depending on multiple variables, including the harvest year; therefore, it is conceivable 359 
that the extent of the associated biological activities may vary as well. Given the low availability of 360 
fruits of the Verdésa variety, we focused on Venégon chestnuts. Hence, additional hydroalcoholic 361 
extracts from the whole fruit of Venégon were prepared from chestnuts collected in 2016 and 2017. 362 
The inhibitory activities (IC50s) exerted by Venégon (2015) and Venégon (2016) were comparable, 363 
while the extract of Venégon (2017) was less effective (Figure 7A). Although we did observe different 364 
degree of activity depending on the harvest year, most likely due to the amount of bioactive 365 
proanthocyanidins, the calculated IC50s were in all cases below 10 µg/mL (fig. 6B). 366 
ini 367 
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Figure 7. Inhibition of IL-8 secretion by extracts from chestnuts harvested in different years in TNF-a-370 
treated AGS cells 371 
 372 
A critical issue in nutraceuticals and botanicals is their fate in the gastro-intestinal tract, 373 
including chemical stability and absorption, which affect the biological activities. Chemical stability 374 
in the stomach environment is certainly highly relevant for extracts and compounds acting directly 375 
on gastric cells. To this end we investigated whether the prevention of IL-8 secretion could be 376 
maintained under the acidic conditions of the stomach and the action of digestive enzymes. The 377 
hydroalcoholic extract of the whole fruit of the Venégon variety (harvest year 2015) was subjected to 378 
in vitro simulated gastric digestion, as described in section 2.7. The simulated digestion only slightly 379 
affected the biological activity of the extract (fig. 8A), increasing the IC50 from 1.50 ± 0.52 to 4.13 ± 380 
1.83 µg/mL (± s.d.), as reported in Figure 8B. 381 
 382 
        B 383 
 384 
Figure 8. IL-8 secretion in TNFα-treated AGS cells in the presence of chestnut extract subjected to in 385 
vitro simulated gastric digestion (A) 386 
IC50  
µg/mL ± s.d. 2015 2016 2017 
Venégon 1.5 ± 0.52 1.34 ± 0.8 6.05 ± 0.92 
IC50  
µg/mL ± s.d. 2015 
2015 
digested 
Venégon 1.5 ± 0.52 4.13 ± 1.83 
A 
 The results shown above indicate that, taking into account critical variables (thermal treatment, 387 
harvest year, gastric digestive environment), Venégon chestnut resulted a valuable source of 388 
bioactive compounds with potential anti-inflammatory activities at the gastric level. 389 
3.4. Biological activity of industrial chestnut flour and related by-product 390 
To verify the practical application of our results, we investigated the biological activity of 391 
hydroalcoholic extracts from finished products (flour) and by-product obtained by industrial 392 
processing of Venégon chestnuts (harvest year 2015). The extract prepared from by-product, 393 
consisting of the not edible parts (pericarp and episperm) and resulting from mechanical peeling, 394 
displayed inhibitory activity on IL-8 secretion (Figure 9A), in line with the results shown in figure 4B 395 
and C; the calculated IC50 was 0.20 ± 0.04 µg/mL (± s.d.), highly similar to that reported in figure 4D. 396 
These results indicate that the mechanical peeling procedure does not alter the potential biological 397 
activity of the not edible chestnut parts. The in vitro gastric digestion did not affect the biological 398 
activity of the extract, as shown in Figure 9B, which still exhibited an IC50 of 0.15 ± 0.02 µg/mL (± s.d.), 399 
consistent with the findings reported in fig. 8A. On the contrary, the extract prepared from industrial 400 
flour, mainly constituted of endosperm, showed absence of activity (Figure 9C), confirming the 401 
results reported in figure 4A. Thus, our data suggest that chestnut-based products prepared 402 
exclusively from endosperm lack anti-inflammatory activity, while industrial by-product may 403 
represent a valuable source of bioactive material. 404 
In the view of improving the nutraceutical properties of chestnut flour, we prepared a 405 
hydroalcoholic extract starting from a mixture of flour and episperm, maintaining the ratio found in 406 
the fruits (22:3, for endosperm and episperm, respectively). We used flour, and episperm from 407 
Venégon fruits harvested in 2015. The extract prepared from flour enriched with episperm (final 408 
concentration 12%, w:w) showed inhibitory activity with an IC50 of 16.35 ± 5.22 µg/mL (± s.d.), as 409 
shown in Figure 9D. 410 
  411 
Figure 9. Hydroalcoholic extracts from chestnuts by-products (var. Venégon) inhibit IL-8 secretion in 412 
TNFα-treated AGS before (A) and after (B) a simulated gastric digestion; extract from chestnut flour 413 
(C) inhibits IL-8 secretion only after enrichment with episperm (12% of final weight) (D). 414 
In conclusion, we demonstrated that chestnut flour is devoid of any anti-inflammatory 415 
activity while industrial by-product retains the ability to inhibit IL-8 secretion. These findings 416 
provide experimental evidence in support of the potential use of chestnut-derived material for 417 
the preparation of nutraceuticals and functional foods, e.g. “fortified” flour. 418 
4. Discussion 419 
Castanea sativa Mill. is a rich source of polyphenols due to its high tannin content, and its fruits 420 
are widely used in food industry for sweets and flour production [61]. Nevertheless, a detailed 421 
phytochemical profile of chestnut fruits, in relation to their biological activities, has not been 422 
investigated in depth. 423 
 By means of a validated bio-guided approach, coupled to a thorough phytochemical analysis, 424 
we were able to isolate the bioactive fraction of chestnut fruits exhibiting anti-inflammatory activity 425 
in gastric cells. This approach was instrumental for the selection of the most appropriate extraction 426 
system (hydroalcoholic mixture vs water), thus resulting more informative than the simple 427 
measurement of the phenolic content. 428 
Proanthocyanidins represent an emerging class of anti-inflammatory compounds and our study 429 
further supports their pharmacological potential in the field of gastric inflammation. The detailed 430 
phytochemical characterization of various chestnut varieties and fruit parts, coupled to the robust 431 
biological assay, allowed us to assign the anti-inflammatory activity to this class of compounds, to 432 
identify the most active varieties and the contribution of the fruit parts. Thus, chestnut fruit, 433 
especially the inner and outer skins, can be included in the list of natural sources of 434 
proanthocyanidins. Moreover, the amount of proanthocyanidins could represent an index to titrate 435 
tannin enriched nutraceuticals. 436 
Although our data clearly show that the edible part of chestnut fruits was not active, the by-437 
product resulted highly enriched in proanthocyanidins and, consequently, with significant anti-438 
inflammatory activity (IC50 < 1 µg/ml). These findings contribute to assessing the health beneficial 439 
value of chestnut-based foods and nutraceuticals, and to the potential valorization of chestnut 440 
processing wastes. 441 
Another outcome of our study is the valorization of Castanea sativa Mill. varieties that combine 442 
appreciated organoleptic properties with high nutraceutical value, such as the Venégon and Verdésa 443 
varieties. Future efforts should be aimed at promoting preservation and cultivation of these varieties, 444 
optimizing the use and manipulation of by-product, with the aim to develop chestnut-based 445 
nutraceuticals and functional foods, with no negative effects on their palatability and taste. These 446 
aspects will be investigated in the near future. 447 
 Our study also provides hints that may result useful for optimizing the processing of chestnut-448 
based products and the treatment of wastes. Elevated temperatures (>100°C) are often used to 449 
facilitate the peeling procedure, to prepare chestnut-based foods (e.g. cakes, pasta, etc.), or to increase 450 
the extraction efficiency in preparing chestnut-derived ingredients. Our data demonstrate that 451 
prolonged exposure (>1 h) at 100°C leads to complete loss of anti-inflammatory activity while upon 452 
treatment at 50°C the biological activity is fully preserved. 453 
Key steps that may influence the biological activities associated to nutraceuticals are their 454 
chemical modifications that may occur during the digestive process and the absorption rate by the 455 
gastro-intestinal tract. In the case of gastric inflammation, absorption may be less relevant since 456 
bioactive compounds can act directly on gastric cells, but resistance to acid environment and enzymes 457 
is a crucial issue. By using an in vitro simulated digestion system, we could demonstrate that chestnut 458 
extracts maintain the ability to prevent IL-8 secretion, thus providing evidence in support of their 459 
potential use in vivo. Moreover, taking into consideration the amount of proanthocyanidins that could 460 
be added to chestnut-based foods (e.g. flour, flakes, etc.), the calculated IC50 reported in the present 461 
study, the approximate gastric volume (30-40 mL), it is conceivable that concentrations sufficient to 462 
obtain anti-inflammatory effects could be easily reached in vivo. 463 
5. Conclusion 464 
Overall, by combining a robust bio-guided approach with a comprehensive analysis of the tannic 465 
fraction of chestnut extracts, we provided evidence for the potential use of chestnut-based 466 
nutraceuticals in human gastritis. The bioactive components of chestnut fruits inhibit IL-8 secretion 467 
most likely by means of multiple mechanisms, including impairment of NF-κB signaling, thus 468 
confirming the importance of this pathway as a general target in the field of anti-inflammatory agents; 469 
on the other hand, the discovery of additional targets would open new applications for inflammation-470 
based diseases. 471 
 The finding that the anti-inflammatory activity is maintained upon treatment in acidic 472 
conditions and with digestive enzymes, further corroborates the applicability of our observations in 473 
human gastritis. Finally, our study also offers hints useful for the valorization of specific chestnut 474 
varieties and for setting up the most appropriate conditions for the preparation of chestnut-based 475 
nutraceuticals with intact biological activities. 476 
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Supplementary material 600 
Fruit variety and  
part used Solvent for extraction Yield (% w/w) 
Paié      
Whole fruit Water 10.3 Water/ethanol 8 
Pericarp  3.3 
Episperm Water/ethanol 16 
Endosperm  9.6 
Piliscé      
Whole fruit Water 12.19 Water/ethanol 12.97 
Pericarp  3.48 
Episperm Water/ethanol 5.16 
Endosperm  15.28 
Russirö     
Whole fruit Water 11.1 Water/ethanol 11.96 
Pericarp  3.48 
Episperm Water/ethanol 0.64 
Endosperm  6.52 
Venégon    
Whole fruit Water 11.4 Water/ethanol 12.6 
Pericarp  6 
Episperm Water/ethanol 21 
Endosperm  14.5 
Verdésa      
Whole fruit Water 16.3 Water/ethanol 8.4 
Pericarp  3.92 
Episperm Water/ethanol 27.9 
Endosperm  16.5 
Aqueous extracts (Water); hydroalcoholic extracts 50:50, ethanol:water (Water/ethanol) 601 
Table S1. Extraction yields expressed as percentage (w/w) in respect to the starting material. 602 
